Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries
ConclusionTreatment of ACS for 12 months with ticagrelor is not a cost-effective option for the prevention of thrombotic events in East Asia.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: China Health | Clopidogrel | Drugs & Pharmacology | Healthcare Costs | Hong Kong Health | Japan Health | Plavix | Study | Taiwan Health